phthalimidine has been researched along with Allergic Encephalomyelitis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aronov, AM; Bandarage, UK; Cao, J; Chin, EY; Collier, PN; Come, JH; Damagnez, V; Davies, RJ; Deininger, D; Doran, JD; Dworakowski, W; Grey, R; Griffith, JP; Henderson, JA; Jacobs, MD; Khare-Pandit, S; Krueger, EB; Le Tiran, A; Liang, J; Liao, Y; Lowe, DB; Mahajan, S; Messersmith, D; Moody, CS; Nanthakumar, S; O'Dowd, H; Pierce, AC; Sizensky, E; Wang, J; Xu, J | 1 |
1 other study(ies) available for phthalimidine and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase γ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS).
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Binding Sites; Biological Availability; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Encephalomyelitis, Autoimmune, Experimental; Enzyme Inhibitors; Humans; Hydrogen Bonding; Isoenzymes; Mice, Inbred C57BL; Multiple Sclerosis; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phthalimides; Structure-Activity Relationship | 2018 |